

21st May 2024

To,
The Manager-Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai-400051,
Maharashtra, India

Sub: **OUTCOME OF BOARD MEETING, DISCLOSURE UNDER REGULATION 30 AND SUBMISSION OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY FOR THE HALF YEAR AND THE FINANCIAL YEAR ENDED 31ST MARCH 2024.**

Ref: **YASONS CHEMEX CARE LIMITED** **SYMBOL: YCCL** **SERIES: SM**

In continuation of our letter dated 14th May 2024, and Pursuant to the Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended from time to time, we wish to inform that the Board of Directors of the Company at their meeting held today i.e., **Tuesday, 21st May 2024** have inter alia considered and approved the following matters:

1. Financial Results:

Approved the Audited Standalone and Consolidated Financial Results of the Company for the Half Year and the Financial Year ended 31st March 2024 along with Auditors' Report issued by the Statutory Auditors M/s H S K & CO LLP, Chartered Accountants (FRN: 117014W/W100685) which have been duly reviewed and recommended by the Audit Committee. In this regard, we are enclosing herewith:

- (a) Auditors' Report on the Audited Standalone and Consolidated Financial Results of the Company for the Half Year and the Financial Year ended 31st March 2024 issued by the Statutory Auditors, M/s H S K & CO LLP, Chartered Accountants (FRN: 117014W/W100685).
- (b) A copy of Audited Standalone and Consolidated Financial Results of the Company for the Half Year and the Financial Year ended 31st March 2024.

We hereby declare that the Company's Statutory Auditors M/s H S K & CO LLP, Chartered Accountants (FRN: 117014W/W100685) have issued Audit Report with an Un-modified opinion on the Audited Standalone and Consolidated Financial Results of the Company for the Half Year and the Financial Year ended 31st March 2024.

The results will be available on the website of the Stock Exchange on the link www.nseindia.com and also on the website of the Company www.yasonschemexcare.com.

2. Appointment of Mr. Rushabh Anilkumar Shah (DIN - 09012222) as an Additional and Independent Director of the Company:

Based on the recommendation of the Nomination and Remuneration Committee and further subject to the approval of Shareholders of the Company, the Board of Directors had appointed Mr. Rushabh Anilkumar Shah (DIN - 09012222) as an Additional Director (Non-Executive and Independent Director) of the Company for a term of 5 (Five) consecutive years commencing from 21st May 2024 till 20th May 2029 (both days inclusive), not be liable to retire by rotation.

Mr. Rushabh Anilkumar Shah (DIN - 09012222) is not disqualified from being appointed as an



Shree Aadinathay Namah

CHEMEX CARE LIMITED

CIN: U24304GJ2017PLC099511 (UAN: GJ01B0086285)

MANUFACTURING OF PERFUMES, DEODORANTS, DYESTUFF & TRADING OF ALL KINDS OF CHEMICALS

Registered Office: 4th floor, 412 Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad -380015.
 Mobile No.9429000479 Ph. No. 079-26730258 email: yccl@yashchemex.com
 web: www.yasonschemexcare.com

Additional Director (Non-Executive and Independent Director) in terms of Section 164 of the Companies Act 2013 and have given his consent to act as an Additional Director (Non-Executive and Independent Director).

Further, the information required under the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are as follows:

S. No	Disclosure Requirements	Details
1	Name	Mr. Rushabh Anilkumar Shah
2	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment of Mr. Rushabh Anilkumar Shah (DIN - 09012222) as an Additional Director (Non-Executive and Independent Director) of the Company for a term of 5 (Five) consecutive years commencing from 21st May 2024 till 20 th May 2029 (both days inclusive), not be liable to retire by rotation. The Appointment is subject to the approval of Shareholders of the Company.
3	Date of appointment/cessation (as applicable) & term of appointment	Date of appointment: - With effect from 21 st May 2024. Term: - 5 (Five) consecutive years commencing from 21st May 2024 till 20 th May 2029 (both days inclusive).
4	Disclosure of relationships between directors	Not related to any of the Directors of the Company.
5	Brief profile (in case of appointment)	Mr. Rushabh Anilkumar Shah holds a degree of bachelor's in commerce, a Professional Degree of Company Secretary and Master of Legislative Laws. He has overall Experience of more than 5 years as a Company Secretary and having relevant experience in the area of Corporate Laws, Security Laws, Capital Market, Corporate Governance, Finance, Leadership as well as various Compliances under Listing Process, Liaison with Regulatory authorities. He is currently associated as a Company Secretary with Mexus Corporation Private Limited and he has been appointed as an Independent Director in following Companies: 1. Yash Chemex Limited. 2. Stitched Textiles Limited. 3. Hindprakash Industries Limited. 4. Vivanta Industries Limited.
6	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/ 2018-19 dated 20th June 2018.	Mr. Rushabh Anilkumar Shah is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

3. Reconstitution of Committee of Board of Directors:

On account of Resignation and Appointment of Independent Directors, the Board of Directors had

approved the reconstitution of the following committees of the Board of the Company as detailed below:

S. No	Name of the Committee	Composition	Designation	Category
1	Audit Committee	Mr. Rushabh Anilkumar Shah	Chairperson	Independent Director
		Ms. Angee Rajendrakumar Shah	Member	Independent Director
		Ms. Silva Kriyangbhai Shah	Member	Independent Director
		Mr. Pritesh Yashwantlal Shah	Member	Managing Director (Executive).
2	Nomination and Remuneration Committee	Mr. Rushabh Anilkumar Shah	Chairperson	Independent Director
		Ms. Angee Rajendrakumar Shah	Member	Independent Director
		Ms. Silva Kriyangbhai Shah	Member	Independent Director
3	Stakeholder's relationship Committee.	Mr. Rushabh Anilkumar Shah	Chairperson	Independent Director
		Ms. Angee Rajendrakumar Shah	Member	Independent Director
		Ms. Silva Kriyangbhai Shah	Member	Independent Director

The Board shall take necessary steps to obtain Shareholders approval in respect of item no: 02 either by way of Annual General Meeting/Extra Ordinary General Meeting/Postal Ballot within due course of time.

The Board meeting commenced at 06:00 PM IST and concluded at 08:15 PM IST.

Kindly consider this and take on record as a requisite disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from to time.

Kindly take the same on your record.

Thanking you,

For Yasons Chemex Care Limited

Pritesh Y. Shah
Managing Director
DIN: 00239655





Independent Auditor's Report Auditor's Report on the Half Yearly and Year to Date Audited Standalone Financial Results of the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended

**To,
The Board of Directors
Yasons Chemex Care Limited
Ahmedabad.**

Report on Audit of the Standalone Financial Results

Opinion

We have audited the accompanying Standalone statement of **Yasons Chemex Care Limited** (the "Company"), for the half year and year ended on March 31, 2024 ("statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us this Standalone financial result:

- i. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (Ind AS) and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the half year ended March, 31 2024 as well as the year to date results for the period from April, 1 2023 to March, 31 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered



Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results


These half yearly standalone financial results as well as the year to date standalone financial results have been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit of the Company and other financial information in accordance with the applicable Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibilities also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of the appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial control that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial results that give a true and fair view and free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our Objectives are to obtain reasonable assurance about whether the Standalone Financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatement can arise from fraud or error and are considered material if,



individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Results.

As a part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists. We are required to draw attention in our auditor's report to the related disclosures in the standalone financial results, or if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial results.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The statement includes the results for the half year and year ended on March, 31 2024 being the balancing figure between the audited figures in respect of the full financial year ended March, 31 2024 and the published unaudited year-to-date figures up to the first half year of the current financial year, which were subjected to a limited review by us, as required under Listing Regulations.

For, H S K & Co LLP
Chartered Accountants
ICAI FRN: 117014W\W100685



Place : Ahmedabad,
Date : May 21,2024

A handwritten signature in blue ink, appearing to be 'Sudhir Shah'.

CA. Sudhir Shah
Partner
Membership No. 115947
UDIN:- 24115947BKAP EG1947

Yasons Chemex Care Limited

(CIN: L24304GJ2017PLC099511)

4th Floor, 412, Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad, Gujarat - 380015 India


E mail ID: cs@yasonschemexcare.com

Website: www.yasonschemexcare.com

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR AND THE FINANCIAL YEAR ENDED 31ST MARCH, 2024

	Particulars	(Rs. In Lakhs, except Earning per Share Value)				
		Half Year Ended			Year Ended	
		31/03/2024	30/09/2023	31/03/2023	31/03/2024	31/03/2023
		Audited	Un-Audited	Audited	Audited	Audited
I	Revenue from operations	2,205.46	2,562.01	2,477.41	4,767.47	3,677.27
II	Other income	4.48	77.33	151.64	81.81	423.37
III	Total income	2,209.95	2,639.34	2,629.05	4,849.28	4,100.64
IV	EXPENSES					
(a)	Cost of materials consumed	1,273.96	1,925.50	1,712.28	3,199.46	2,484.05
(b)	Purchases of stock-in-trade	1,121.58	327.34	1,138.75	1,448.92	1,538.85
(c)	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(210.80)	58.23	(400.45)	(152.57)	(471.60)
(d)	Employee benefit expense	52.22	5.47	6.77	57.69	14.70
(e)	Finance costs	48.10	29.32	23.35	77.42	41.08
(f)	Depreciation and amortisation expense	5.11	5.11	5.04	10.22	10.10
(g)	Other expenses	42.08	16.68	48.03	58.76	62.06
	Total expenses	2,332.25	2,367.67	2,533.77	4,699.91	3,679.24
V	Profit/(Loss) before tax	(122.30)	271.67	95.27	149.38	421.39
VI	Tax expense					
(1)	Current tax	(25.46)	53.06	13.60	27.60	71.10
(2)	Deferred tax charge/(credit)	(6.99)	(0.64)	0.01	(7.63)	(0.23)
(3)	Tax In Respect of Earlier Years	5.31	-	7.76	5.31	7.76
	Total tax expense	(27.14)	52.42	21.37	25.28	78.63
VII	Profit/(Loss) for the period	(95.15)	219.25	73.91	124.10	342.77
VIII	Other comprehensive income					
(i)	Items that will not be reclassified to profit or loss	(1.62)	-	0.43	(1.62)	0.43
(ii)	Income tax relating to items that will not be reclassified to profit or loss	0.41	-	(0.11)	0.41	(0.11)
IX	Total comprehensive income for the period (VII+VIII)	(96.36)	219.25	74.23	122.89	343.09
X	Paid-Up Equity Share Capital of Face Value Rs.10/- Each	1,930.39	1,930.39	1,416.19	1,930.39	1,416.19
XI	Reserve Excluding Revaluation Reserves				1,977.26	655.94
XII	Basic & diluted earnings per share of face value of Rs.10 each fully paid up					
(1)	Basic	(0.68)	1.38	0.52	0.70	2.42
(2)	Diluted	(0.68)	1.38	0.52	0.70	2.42

For, Yasons Chemex Care Limited



Pritesh Y. Shah
Managing Director
(DIN: 00239665)



Place: Ahmedabad
Date: May 21, 2024



YASONS CHEMEX CARE LIMITED

Yasons Chemex Care Limited

(CIN: L24304GJ2017PLC099511)

4th Floor, 412, Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad,
Gujarat-380015 India

E mail ID: cs@yasonschemexcare.com

Website: www.yasonschemexcare.com

AUDITED STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2024

(Rs. In Lakhs)

Particulars		As at March 31, 2024	As at March 31, 2023
A	ASSETS	Audited	Audited
1	Non-current assets		
	(a) Property, plant and equipment	43.19	51.72
	(b) Capital work-in-progress	-	-
	(c) Financial assets		
	(i) Non Current Investment	724.88	658.69
	(ii) Loans	-	-
	(iii) Other financial assets	42.35	20.69
	(d) Deferred Tax Assets	9.20	1.16
	(e) Non Current Assets	1.68	1.68
	Total non - current assets	821.30	733.94
2	Current assets		
	(a) Inventories	1,075.44	805.46
	(b) Financial assets		
	(i) Investments	-	-
	(i) Trade receivables	2,609.24	1,139.01
	(ii) Cash and cash equivalents	15.47	8.44
	(iv) Other bank balances	-	-
	(v) Loans	-	-
	(iii) Bank Balance other than Cash and Cash Equivalents	-	-
	(iv) Other financial assets	-	-
	(c) Current Tax Assets (Net)	-	-
	(c) Other current assets	153.95	71.74
	Total current assets	3,854.10	2,024.65
	Total assets (1+2)	4,675.40	2,758.59



YASONS CHEMEX CARE LIMITED


Yasons Chemex Care Limited

B	EQUITY AND LIABILITIES			
	1	Equity		
		(a) Equity share capital	1,930.39	1,416.19
		(b) Other equity	1,977.26	655.94
		Total equity	3,907.65	2,072.13
		LIABILITIES		
	2	Non-current liabilities		
		(a) Financial liabilities		
		Borrowings	42.08	77.37
		(b) Provisions	4.27	-
		Total non - current liabilities	46.35	77.37
	3	Current liabilities		
		(a) Financial liabilities		
		(i) Borrowings	433.11	269.03
		(ii) Trade payables	-	-
		- Total Outstanding dues of micro enterprises and small enterprises	-	-
		- Total Outstanding dues of creditors other than micro enterprises and small enterprises	226.03	292.19
		(ii) Other financial liabilities	-	-
		(b) Other current liabilities	42.60	1.35
		(c) Provisions	0.03	0.74
		(d) Current tax liabilities (Net)	19.63	45.76
		Total current liabilities	721.40	609.08
		Total equity and liabilities (1+2+3)	4,675.40	2,758.59

For, Yasons Chemex Care Limited




Pritesh Y. Shah
Managing Director
(DIN: 00239665)



Place: Ahmedabad
Date: May 21, 2024

YASONS CHEMEX CARE LIMITED

<p>Yasons Chemex Care Limited (CIN: L24304GJ2017PLC099511) 4th Floor, 412, Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad, Gujarat-380015 India E mail ID: cs@yasonschemexcare.com Website: www.yasonschemexcare.com Standalone Statement of Cash Flow for the Financial year ended March 31, 2024</p>		
(Rs. in Lakhs)		
Particulars	Year Ended March 31, 2024	Year Ended March 31, 2023
	Audited	Audited
Cash flow from operating activities		
Profit Before tax	149.38	421.39
Adjustments for :		
Depreciation and amortisation expense	10.22	10.10
Provision for expected credit loss	25.00	2.18
Finance costs	77.42	41.08
Share of Profit from Investment in LLP	(66.19)	(143.49)
Interest income	(1.21)	(5.82)
Operating profit before working capital changes	194.62	325.44
Changes in operating assets and liabilities:		
(Increase)/Decrease in inventories	(269.98)	(394.56)
(Increase)/Decrease in trade receivables	(1,495.24)	95.02
(Increase)/Decrease in Other current financial assets , other current assets , Loans (Current + Non Current)	(105.49)	455.63
Increase/(Decrease) in trade payable	(66.16)	(293.77)
Increase/(Decrease) in other current financial liabilities, other current liabilities , Provisions (Current + Non Current)	44.81	(158.51)
Cash flow generated from operations	(1,697.45)	29.26
Direct taxes paid (net)	(59.04)	(56.12)
NET CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES	(1,756.49)	(26.86)
Cash flows from investing activities		
Purchase of property, plant and equipments (Net)	(1.69)	(0.14)
Interest received	1.21	5.82
NET CASH FLOW FROM / (USED IN) IN INVESTING	(0.48)	5.68
Cash flows from financing activities		
Finance costs paid	(77.42)	(41.08)
Proceeds from Issue of Equity Shares (Including Security Premium Reserve and net of Issue of Shares (IPO) Expenses)	1,712.63	-
Proceeds from Non-current and Current borrowings (Net)	128.79	65.00
NET CASH FLOW FROM / (USED IN) FINANCING ACTIVITIES	1,764.00	23.92
NET INCREASED / (DECREASED) IN CASH AND CASH EQUIVALENTS (A + B + C)	7.03	2.74
Cash and cash equivalents at the beginning of the year	8.44	5.70
Cash and cash equivalents at the end of the year	15.47	8.44
Notes:		
(i). The above cash flow statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard - 7 Cash Flow Statements specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014.		
(ii). Previous Period's / Year's figures have been re-grouped / Re-Classified where necessary to make it comparable with the current period.		
<p>For, Yasons Chemex Care Limited</p> <p> Pritesh Y. Shah Managing Director (DIN: 00239665)</p> <p>Place: Ahmedabad Date: May 21, 2024</p>		



Yasons Chemex Care Limited

(CIN: L24304GJ2017PLC099511)

4th Floor, 412, Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad, Gujarat-380015 India

E mail ID: cs@yasonskemexcare.com

Website: www.yasonskemexcare.com

NOTES TO AUDITED STANDALONE FINANCIAL RESULTS FOR THE HALF YEAR AND THE FINANCIAL YEAR ENDED 31ST MARCH, 2024

- The above Audited Standalone Financial Results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors of the Company at their respective meetings held on Tuesday, May 21, 2024. The Statutory Auditor of the Company
- 1 have carried out Statutory Audit of the above Audited Standalone Financial Results for the Half Year and the Financial Year ended March 31, 2024 as per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The Statutory Auditors Report is annexed herewith. The Statutory Auditors have expressed an unmodified opinion.
 - 2 The above Audited Standalone Financial Results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices.
 - 3 The Company operates in a single segment and in line with Ind AS - 108 - "Operating Segments", the operation of the Company fall under only one Business which is considered to be the only reportable business segment.
 - 4 The figures of second half of the year are the balancing figures between audited figures in respect of the full financial year and the published year to-date figures up to the first half year ended on September 30, 2023 of the current financial year.
 - 5 The figures for the previous period has been regrouped / re-arranged to make them comparable with the current period figures.
- The Audited Standalone Financial Results are available on the Company's website and also on the website of the NSE where the
- 6 shares of the Company are listed.
- During the Financial Year ended 31st March 2024, the Company had raised INR 2056.80 Lakhs by way of issue and allotment of 51420000 fully paid up Equity Shares at an issue price of INR 40 per Equity Share by way of Initial Public office. The Allotment has been done on 31st July 2023. The Equity Shares of the Company are currently listed on Emerge Platform of National Stock Exchange
- 7 of India Limited ("NSE").

For, Yasons Chemex Care Limited



Pritesh Y. Shah
Managing Director
(DIN: 00239665)



Place: Ahmedabad

Date: May 21, 2024



Independent Auditor's Report Auditor's Report on the Half Yearly and Year to Date Audited Consolidated Financial Results of the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended

**To,
The Board of Directors
Yasons Chemex Care Limited
Ahmedabad.**

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying consolidated financial results of **Yasons Chemex Care Limited** ('the Company') and its subsidiary for the half year and year ended March 31, 2024 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of report of other auditors on separate audited financial results of subsidiary, these consolidated financial results:

- include the financial results of Rishit Polysurf LLP (a subsidiary)
- are presented in accordance with the requirements of Regulation 33 of Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (Ind AS) and other accounting principles generally accepted in India of the consolidated net profit and other comprehensive income and other financial information for the half year ended March, 31 2024 as well as the year to date results for the period from April, 1 2023 to March, 31 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Companies Act, 2013 ('the Act'). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Results* section of our report. We are independent of the Company in accordance



with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Consolidated Financial Results

The Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of the Consolidated financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the net consolidated profit/loss and other comprehensive income and other financial information in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the Company and its subsidiary are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial results, the respective Board of Directors of the Company and of its subsidiary are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Company and its subsidiary are also responsible for overseeing the financial reporting process of the Company and its subsidiary.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material



misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions; misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether



the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the Company and its subsidiary to express an opinion on the consolidated financial results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the consolidated financial results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the consolidated financial results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the consolidated financial results.

We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matter


- a. The consolidated financial results include the Company's share of net profit of Rs. 66.19 Lakhs for the year ended March 31, 2024, as considered in the consolidated financial results, in respect of one subsidiary, whose financial statements have not been audited by us. These financial statements have been audited by other auditors whose report have been furnished to us by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts



and disclosures included in respect of an subsidiary, is based solely on the reports of the other auditors.

Our opinion on the consolidated financial results is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.

For, H S K & Co LLP
Chartered Accountants
ICAI FRN: 117014W\W100685




A handwritten signature in blue ink, appearing to be "Sudhir S Shah".

Place : Ahmedabad,
Date : May 21,2024

CA. Sudhir S Shah
Partner
Membership No. 115947
UDIN:- 241159478KAPET8922

Yasons Chemex Care Limited (CIN: L24304GJ2017PLC099511) 4th Floor, 412, Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad, Gujarat - 380015 India E mail ID: cs@yasonschemexcare.com Website: www.yasonschemexcare.com					
STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR AND THE FINANCIAL YEAR ENDED 31ST MARCH, 2024					
Particulars	(Rs. In Lakhs, except Earning per Share Value)				
	Half Year Ended			Year Ended	
	31/03/2024	30/09/2023	31/03/2023	31/03/2024	31/03/2023
	Audited	Un-Audited	Audited	Audited	Audited
I Revenue from operations	3,170.92	3,753.40	2,477.41	6,924.32	3,677.27
II Other income	(11.38)	106.93	151.64	95.55	423.37
III Total income	3,159.54	3,860.33	2,629.05	7,019.87	4,100.64
IV EXPENSES					
(a) Cost of materials consumed	2,171.50	3,024.49	1,712.28	5,195.99	2,484.05
(b) Purchases of stock-in-trade	1,121.58	327.34	1,138.75	1,448.92	1,538.85
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(210.80)	58.23	(400.45)	(152.57)	(471.60)
(d) Employee benefit expense	76.14	5.47	6.77	81.61	14.70
(e) Finance costs	83.54	49.37	23.35	132.91	41.08
(f) Depreciation and amortisation expense	21.43	21.43	5.04	42.86	10.10
(g) Other expenses	50.05	39.66	48.03	89.71	62.05
Total expenses	3,313.45	3,526.01	2,533.77	6,839.44	3,679.24
V Profit before tax	(153.91)	334.32	95.27	180.43	421.39
VI Tax expense					
(1) Current tax	4.93	53.06	13.60	57.99	71.10
(2) Deferred tax charge\ (credit)	(6.99)	(0.64)	0.01	(7.63)	(0.23)
(3) Tax In Respect of Earlier Years	5.31	-	7.76	5.31	7.76
Total tax expense	3.25	52.42	21.37	55.67	78.63
VII Profit for the period	(157.16)	281.90	73.91	124.76	342.77
VIII Other comprehensive income					
(i) Items that will not be reclassified to profit or loss	(1.62)	-	0.43	1.62	0.43
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.41	-	(0.11)	0.41	(0.11)
IX Total comprehensive income for the period (VII+VIII)	(158.37)	281.90	74.23	123.55	343.09
X Paid-Up Equity Share Capital of Face Value Rs.10/- Each	1,930.39	1,930.39	1,416.19	1,930.39	1,416.19
XI Reserve Excluding Revaluation Reserves				1,977.26	655.94
XII Basic & diluted earnings per share of face value of Rs.10 each fully paid up					
(1) Basic	(1.06)	1.77	0.52	0.71	2.42
(2) Diluted	(1.06)	1.77	0.52	0.71	2.42

For, Yasons Chemex Care Limited



Yasons Chemex Care Limited

INDIA

Ahmedabad

Pritesh Y. Shah

Managing Director

(DIN: 00239665)

Place: Ahmedabad

Date: May 21,2024

CHARTERED ACCOUNTANTS

SK & COLLP


AHMEDABAD

For, Yasons Chemex Care Limited



Pritesh Y. Shah
Managing Director
(DIN: 00239665)

Place: Ahmedabad
Date: May 21, 2024



YASONS CHEMEX CARE LIMITED

Yasons Chemex Care Limited
(CIN: L24304GJ2017PLC099511)

4th Floor, 412, Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad,
Gujarat-380015 India

E mail ID: cs@yasonskemexcare.com

Website: www.yasonskemexcare.com

AUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2024
(Rs. In Lakhs)

Particulars		As at March 31, 2024	As at March 31, 2023
A	ASSETS	Audited	Audited
1	Non-current assets		
	(a) Property, plant and equipment	288.36	51.72
	(b) Capital work-in-progress	-	-
	(c) Goodwill	27.11	-
	(d) Financial assets		
	(i) Non Current Investment	-	658.69
	(ii) Loans	-	-
	(iii) Other financial assets	42.35	20.69
	(e) Deferred Tax Assets	9.20	1.16
	(f) Non Current Assets	1.68	1.68
	Total non - current assets	368.70	733.94
2	Current assets		
	(a) Inventories	1,492.65	805.46
	(b) Financial assets		
	(i) Investments	-	-
	(i) Trade receivables	2,870.11	1,139.01
	(ii) Cash and cash equivalents	146.03	8.44
	(iv) Other bank balances	-	-
	(v) Loans	-	-
	(iii) Bank Balance other than Cash and Cash Equivalents	-	-
	(iv) Other financial assets	-	-
	(c) Current Tax Assets (Net)	-	-
	(c) Other current assets	581.99	71.74
	Total current assets	5,090.78	2,024.65
	Total assets (1+2)	5,459.48	2,758.59



Yasons Chemex Care Limited		
B	EQUITY AND LIABILITIES	
1	Equity	
	(a) Equity share capital	1,930.39 1,416.19
	(b) Other equity	1,977.26 655.94
	Equity attributable to equity holders of the company	3,907.65 2,072.13
	(c) Non-controlling interest	7.05 -
	Total Equity	3,914.70 2,072.13
	LIABILITIES	
2	Non-current liabilities	
	(a) Financial liabilities	
	Borrowings	42.08 77.37
	(b) Provisions	4.27 -
	Total non - current liabilities	46.35 77.37
3	Current liabilities	
	(a) Financial liabilities	
	(i) Borrowings	809.24 269.03
	(ii) Trade payables	- -
	- Total Outstanding dues of micro enterprises and small enterprises	- -
	- Total Outstanding dues of creditors other than micro enterprises and small enterprises	470.97 292.19
	(ii) Other financial liabilities	- -
	(b) Other current liabilities	169.63 1.35
	(c) Provisions	0.13 0.74
	(d) Current tax liabilities (Net)	48.46 45.76
	Total current liabilities	1,498.43 609.08
	Total equity and liabilities (1+2+3)	5,459.48 2,758.59

For, Yasons Chemex Care Limited




Pritesh Y. Shah
Managing Director
(DIN: 00239665)



Place: Ahmedabad

Date: May 21, 2024

Yasons Chemex Care Limited (CIN: L24304GJ2017PLC099511) 4th Floor, 412, Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad, Gujarat-380015 India E mail ID: cs@yasonschemexcare.com Website: www.yasonschemexcare.com Consolidated Statement of Cash Flow for the Financial year ended March 31, 2024		
(Rs. in Lakhs)		
Particulars	Year Ended March 31, 2024	Year Ended March 31, 2023
Cash flow from operating activities		
Profit Before tax	180.44	421.39
Adjustments for :		
Depreciation and amortisation expense	42.86	10.10
Provision for expected credit loss	25.00	2.18
Finance costs	132.91	41.08
Share of Profit from Investment In LLP	-	(143.49)
Interest income	(1.21)	(5.82)
Operating profit before working capital changes	380.00	325.44
Changes in operating assets and liabilities:		
(Increase)/Decrease in inventories	(327.41)	(394.56)
(Increase)/Decrease in trade receivables	(1,184.18)	95.02
(Increase)/Decrease in Other current financial assets , other	(210.26)	455.63
Increase/(Decrease) in trade payable	(150.28)	(293.77)
Increase/(Decrease) in other current financial liabilities, other current liabilities , Provisions (Current + Non Current)	(64.67)	(158.51)
Cash flow generated from operations	(1,556.80)	29.26
Direct taxes paid (net)	(65.44)	(56.12)
NET CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES	(1,622.24)	(26.86)
Cash flows from investing activities		
Purchase of property, plant and equipments (Net)	(1.69)	(0.14)
Interest received	1.21	5.82
NET CASH FLOW FROM / (USED IN) IN INVESTING	(0.48)	5.68
Cash flows from financing activities		
Finance costs paid	(132.91)	(41.08)
Proceeds from Issue of Equity Shares (Including Security Premium Reserve and net of Issue of Shares (IPO) Expenses)	1,712.63	-
Proceeds from Non-current borrowings (Net)	180.58	65.00
NET CASH FLOW FROM / (USED IN) FINANCING ACTIVITIES	1,760.31	23.92
NET INCREASED / (DECREASED) IN CASH AND CASH EQUIVALENTS (A + B + C)	137.59	2.74
Cash and cash equivalents at the beginning of the year	8.44	5.70
Cash and cash equivalents at the end of the year	146.03	8.44
Notes:		
(i). The above cash flow statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard - 7 Cash Flow Statements specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014.		
(ii). Previous Period's / Year's figures have been re-grouped / Re-Classified where necessary to make it comparable with the current period.		
For, Yasons Chemex Care Limited  Pritesh Y. Shah Managing Director (DIN: 00239665) Place: Ahmedabad Date: May 21, 2024		

Yasons Chemex Care Limited

(CIN: L24304GJ2017PLC099511)

4th Floor, 412, Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad, Gujarat-380015 India

E mail ID: cs@yasonchemexcare.com

Website: www.yasonchemexcare.com

NOTES TO AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR AND THE FINANCIAL YEAR ENDED 31ST MARCH, 2024

The above Audited Consolidated Financial Results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors of the Company at their respective meetings held on Tuesday, May 21, 2024. The Statutory Auditor of the Company have carried out Statutory Audit of the above Audited Consolidated Financial Results for the Half Year and the Financial Year ended March 31, 2024 as per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The Statutory Auditors Report is annexed herewith. The Statutory Auditors have expressed an unmodified opinion.

The above Audited Consolidated Financial Results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

The Audited Consolidated Financial Results for the Half Year and the Financial Year ended March 31, 2024 includes results of its Subsidiary entity : **Rishit Polysurf LLP**.

The Company operates in a single segment and in line with Ind AS - 108 - "Operating Segments", the operation of the Company fall under only one Business which is considered to be the only reportable business segment.

The figures of second half of the year are the balancing figures between audited figures in respect of the full financial year and the published year to-date figures up to the first half year ended on September 30, 2023 of the current financial year.

The figures for the presented period has been regrouped / re-arranged to make them comparable with the current period figures.

The Audited Consolidated Financial Results are available on the Company's website and also on the website of the NSE where the shares of the Company are listed.

During the Financial Year ended 31st March 2024, the Company had raised INR 2056.80 Lakhs by way of issue and allotment of 51420000 fully paid up Equity Shares at an issue price of INR 40 per Equity Share by way of Initial Public offer. The Allotment has been done on 31st July 2023. The Equity Shares of the Company are currently listed on Emerge Platform of National Stock Exchange of India Limited ("NSE").

For, Yasons Chemex Care Limited



Pritesh Y. Shah
Managing Director
(DIN: 00239665)



Place: Ahmedabad

Date: May 21, 2024



Shree Aadinathay Namah

CHEMEX CARE LIMITED

CIN: U24304GJ2017PLC099511 (UAN: GJ01B0086285)

MANUFACTURING OF PERFUMES, DEODORANTS, DYESTUFF & TRADING OF ALL KINDS OF CHEMICALS

Registered Office: 4th floor, 412 Sigma Icon-1, 132ft Ring Road, Opp. Medilink Hospital, Satellite, Ahmedabad -380015.
Mobile No.9429000479 Ph. No. 079-26730258 email: yccl@yashchemex.com
web: www.yasonschemexcare.com

21st May 2024

To,
The Manager-Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400051,
Maharashtra, India

Ref: YASONS CHEMEX CARE LIMITED SYMBOL: YCCL SERIES: SM

Sub.: DECLARATION FOR UN-MODIFIED OPINION WITH AUDIT REPORT ON AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY FOR THE HALF YEAR AND THE FINANCIAL YEAR ENDED 31ST MARCH 2024.

Dear Sir,


This is in reference to the Regulation 33 (3)(d) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 as amended by the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2016 vide Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated 25/05/2016.

We, hereby confirm and declare that the Company's Statutory Auditors M/s H S K & CO LLP, Chartered Accountants (FRN: 117014W/W100685) have issued Audit Report with an Un-modified opinion on the Audited Standalone and Consolidated Financial Results of the Company for the Half Year and the Financial Year ended 31st March 2024.

Kindly take the same on your record.

Thanking you,

For Yasons Chemex Care Limited


Pritesh Y. Shah
Managing Director
DIN: 00239655

